{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:01:17Z","timestamp":1792144877777,"version":"4.4.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003186","name":"Fredrik och Ingrid Thurings Stiftelse","doi-asserted-by":"publisher","award":["2019-00510"],"award-info":[{"award-number":["2019-00510"]}],"id":[{"id":"10.13039\/501100003186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007508","name":"Stiftelsen Sigurd and Elsa Goljes Minne","doi-asserted-by":"publisher","award":["LA2019-0164"],"award-info":[{"award-number":["LA2019-0164"]}],"id":[{"id":"10.13039\/501100007508","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008587","name":"Stiftelsen Psykiatriska Forskningsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2018-02814"],"award-info":[{"award-number":["2018-02814"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-01346"],"award-info":[{"award-number":["2020-01346"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2015-02894"],"award-info":[{"award-number":["2015-02894"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-02105"],"award-info":[{"award-number":["2020-02105"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009535","name":"Systembolaget","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009535","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kurt och Ingrid Dahr\u00e9ns Stiftelse and governmental support under the LUA\/ALF agreement"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Schizophrenia is associated with three main categories of symptoms; positive, negative and cognitive. Of these, only the positive symptoms respond well to treatment with antipsychotics. Due to the lack of effect of antipsychotics on negative symptoms, it has been suggested that while the positive symptoms are related to a hyperdopaminergic state in associative striatum, the negative symptoms may be a result of a reduced dopamine (DA) activity in the nucleus accumbens (nAc). Drug abuse is common in schizophrenia, supposedly alleviating negative symptomatology. Some, but not all, drugs aggravate psychosis, tentatively due to differential effects on DA activity in striatal regions. Here this hypothesis was tested in rats by using a double-probe microdialysis technique to simultaneously assess DA release in the nAc and associative striatum (dorsomedial striatum; DMS) following administration of the psychosis-generating substances amphetamine (0.5\u2009mg\/kg), cocaine (15\u2009mg\/kg) and \u0394<jats:sup>9<\/jats:sup>-tetrahydrocannabinol (THC, 3\u2009mg\/kg), and the generally non-psychosis-generating substances ethanol (2.5\u2009g\/kg), nicotine (0.36\u2009mg\/kg) and morphine (5\u2009mg\/kg). The data show that amphetamine and cocaine produce identical DA elevations both in the nAc and DMS, whereas nicotine increases DA in nAc only. Ethanol and morphine both increased DMS DA, but weaker and in a qualitatively different way than in nAc, suggesting that the manner in which DA is increased might be important to the triggering of psychosis. THC elevated DA in neither region, indicating that the pro-psychotic effects of THC are not related to DA release. We conclude that psychosis-generating substances affect striatal DA release differently than non-psychosis-generating substances.<\/jats:p>","DOI":"10.1038\/s41398-021-01589-z","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T08:03:03Z","timestamp":1631520183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Differential dopamine release by psychosis-generating and non-psychosis-generating addictive substances in the nucleus accumbens and dorsomedial striatum"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6229-7178","authenticated-orcid":false,"given":"Klara","family":"Danielsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"Stomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-9908","authenticated-orcid":false,"given":"Louise","family":"Adermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Ericson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"S\u00f6derpalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"1589_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J van Os","year":"2009","unstructured":"van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635\u201345.","journal-title":"Lancet."},{"key":"1589_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s004060070002","volume":"250","author":"A Jablensky","year":"2000","unstructured":"Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000;250:274\u201385.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1589_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","volume":"15","author":"W Rossler","year":"2005","unstructured":"Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15:399\u2013409.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1589_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","volume":"382","author":"HA Whiteford","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575\u201386.","journal-title":"Lancet."},{"key":"1589_CR5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","volume":"363","author":"KT Mueser","year":"2004","unstructured":"Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363:2063\u201372.","journal-title":"Lancet."},{"key":"1589_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114:169\u201379.","journal-title":"Br Med Bull"},{"key":"1589_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend"},{"key":"1589_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-0173(94)90012-4","volume":"19","author":"G Ellison","year":"1994","unstructured":"Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Res Rev. 1994;19:223\u201339.","journal-title":"Brain Res Rev"},{"key":"1589_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/YCO.0000000000000254","volume":"29","author":"JG Bramness","year":"2016","unstructured":"Bramness JG, Rognli EB. Psychosis induced by amphetamines. Curr Opin Psychiatry. 2016;29:236\u201341.","journal-title":"Curr Opin Psychiatry"},{"key":"1589_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/15504263.2014.906133","volume":"10","author":"Y Tang","year":"2014","unstructured":"Tang Y, Martin NL, Cotes RO. Cocaine-induced psychotic disorders: presentation, mechanism, and management. J Dual Diagn. 2014;10:98\u2013105.","journal-title":"J Dual Diagn"},{"key":"1589_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev.ne.19.030196.001535","volume":"19","author":"RA Wise","year":"1996","unstructured":"Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci. 1996;19:319\u201340.","journal-title":"Annu Rev Neurosci"},{"key":"1589_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1460-9568.2012.07990.x","volume":"35","author":"KC Berridge","year":"2012","unstructured":"Berridge KC. From prediction error to incentive salience: mesolimbic computation of reward motivation. Eur J Neurosci. 2012;35:1124\u201343.","journal-title":"Eur J Neurosci"},{"key":"1589_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1126\/science.2903550","volume":"242","author":"GF Koob","year":"1988","unstructured":"Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988;242:715\u201323.","journal-title":"Science."},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00213-006-0405-4","volume":"187","author":"G Juckel","year":"2006","unstructured":"Juckel G, Schlagenhauf F, Koslowski M, Filonov D, W\u00fcstenberg T, Villringer A, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology. 2006;187:222\u20138.","journal-title":"Psychopharmacology"},{"key":"1589_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/schbul\/sbu026","volume":"40","author":"DH Wolf","year":"2014","unstructured":"Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA, et al. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. Schizophr Bull. 2014;40:1328\u201337.","journal-title":"Schizophr Bull"},{"key":"1589_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/syn.890210207","volume":"21","author":"RA Wise","year":"1995","unstructured":"Wise RA, Leone P, Rivest R, Leeb K. Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse. 1995;21:140\u20138.","journal-title":"Synapse."},{"key":"1589_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1176\/ajp.137.12.1518","volume":"137","author":"SJ Peroutka","year":"1980","unstructured":"Peroutka SJ, Synder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry. 1980;137:1518\u201322.","journal-title":"Am J Psychiatry"},{"key":"1589_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","volume":"20","author":"A Carlsson","year":"1963","unstructured":"Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharm Toxicol. 1963;20:140\u20134.","journal-title":"Acta Pharm Toxicol"},{"key":"1589_CR19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(78)90193-9","volume":"1","author":"EC Johnstone","year":"1978","unstructured":"Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet. 1978;1:848\u201351.","journal-title":"Lancet."},{"key":"1589_CR20","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","volume":"97","author":"A Abi-Dargham","year":"2000","unstructured":"Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000;97:8104\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1589_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0006-3223(99)00067-0","volume":"46","author":"M Laruelle","year":"1999","unstructured":"Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46:56\u201372.","journal-title":"Biol Psychiatry"},{"key":"1589_CR22","doi-asserted-by":"publisher","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","volume":"93","author":"M Laruelle","year":"1996","unstructured":"Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235\u201340.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1589_CR23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.11.1550","volume":"155","author":"A Abi-Dargham","year":"1998","unstructured":"Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 1998;155:761\u20137.","journal-title":"Am J Psychiatry"},{"key":"1589_CR24","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","volume":"44","author":"R McCutcheon","year":"2018","unstructured":"McCutcheon R, Beck K, Jauhar S, Howes OD. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2018;44:1301\u201311.","journal-title":"Schizophr Bull"},{"key":"1589_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.108.147058","volume":"329","author":"M Ericson","year":"2009","unstructured":"Ericson M, L\u00f6f E, Stomberg R, S\u00f6derpalm B. The Smoking Cessation Medication Varenicline Attenuates Alcohol and Nicotine Interactions in the Rat Mesolimbic Dopamine System. J Pharmacol Exp Ther. 2009;329:225\u201330. https:\/\/doi.org\/10.1124\/jpet.108.147058.","journal-title":"J Pharmacol Exp Ther"},{"key":"1589_CR26","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1073\/pnas.85.14.5274","volume":"85","author":"G Di Chiara","year":"1988","unstructured":"Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 1988;85:5274\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1589_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuropharm.2014.03.010","volume":"82","author":"S Jonsson","year":"2014","unstructured":"Jonsson S, Adermark L, Ericson M, Soderpalm B. The involvement of accumbal glycine receptors in the dopamine-elevating effects of addictive drugs. Neuropharmacology. 2014;82:69\u201375.","journal-title":"Neuropharmacology."},{"key":"1589_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/alcalc\/agu047","volume":"49","author":"RB Clarke","year":"2014","unstructured":"Clarke RB, Adermark L, Chau P, Soderpalm B, Ericson M. Increase in nucleus accumbens dopamine levels following local ethanol administration is not mediated by acetaldehyde. Alcohol Alcohol. 2014;49:498\u2013504.","journal-title":"Alcohol Alcohol"},{"key":"1589_CR29","unstructured":"Paxinos G. The rat brain in stereotaxic coordinates. 6. ed. ed. Amsterdam [u.a.]: Amsterdam u.a. : Elsevier, Academic Press; 2007. ."},{"key":"1589_CR30","doi-asserted-by":"publisher","first-page":"172831","DOI":"10.1016\/j.pbb.2019.172831","volume":"188","author":"L Ulenius","year":"2020","unstructured":"Ulenius L, Andren A, Adermark L, Soderpalm B, Ericson M. Sub-chronic taurine administration induces behavioral sensitization but does not influence ethanol-induced dopamine release in the nucleus accumbens. Pharm Biochem Behav. 2020;188:172831.","journal-title":"Pharm Biochem Behav"},{"key":"1589_CR31","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/mp.2016.252","volume":"23","author":"J Vaucher","year":"2018","unstructured":"Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2018;23:1287\u201392.","journal-title":"Mol Psychiatry"},{"key":"1589_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.biopsych.2015.08.001","volume":"79","author":"SH Gage","year":"2016","unstructured":"Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79:549\u201356.","journal-title":"Biol Psychiatry"},{"key":"1589_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1176\/appi.ajp.2019.18101217","volume":"176","author":"KS Kendler","year":"2019","unstructured":"Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. Am J Psychiatry. 2019;176:711\u20139.","journal-title":"Am J Psychiatry"},{"key":"1589_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuropharm.2015.06.001","volume":"97","author":"L Adermark","year":"2015","unstructured":"Adermark L, Morud J, Lotfi A, Jonsson S, S\u00f6derpalm B, Ericson M. Age-contingent influence over accumbal neurotransmission and the locomotor stimulatory response to acute and repeated administration of nicotine in Wistar rats. Neuropharmacology. 2015;97:104\u201312.","journal-title":"Neuropharmacology."},{"key":"1589_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/syn.890160105","volume":"16","author":"M Nisell","year":"1994","unstructured":"Nisell M, Nomikos GG, Svensson TH. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse. 1994;16:36\u201344.","journal-title":"Synapse."},{"key":"1589_CR36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S0091-3057(97)00527-3","volume":"59","author":"A Kankaanpaa","year":"1998","unstructured":"Kankaanpaa A, Meririnne E, Lillsunde P, Seppala T. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharm Biochem Behav. 1998;59:1003\u20139.","journal-title":"Pharm Biochem Behav"},{"key":"1589_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/syn.20489","volume":"62","author":"ST Frank","year":"2008","unstructured":"Frank ST, Krumm B, Spanagel R. Cocaine-induced dopamine overflow within the nucleus accumbens measured by in vivo microdialysis: a meta-analysis. Synapse. 2008;62:243\u201352.","journal-title":"Synapse."},{"key":"1589_CR38","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0028-3908(91)90145-2","volume":"30","author":"P Rada","year":"1991","unstructured":"Rada P, Mark GP, Pothos E, Hoebel BG. Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology. 1991;30:1133\u20136.","journal-title":"Neuropharmacology."},{"key":"1589_CR39","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1111\/acer.13246","volume":"40","author":"AA Vena","year":"2016","unstructured":"Vena AA, Mangieri R, Gonzales RA. Regional analysis of the pharmacological effects of acute ethanol on extracellular striatal dopamine activity. Alcohol Clin Exp Res. 2016;40:2528\u201336.","journal-title":"Alcohol Clin Exp Res"},{"key":"1589_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00213-007-0879-8","volume":"195","author":"P Robledo","year":"2007","unstructured":"Robledo P, Trigo JM, Panayi F, de la Torre R, Maldonado R. Behavioural and neurochemical effects of combined MDMA and THC administration in mice. Psychopharmacology. 2007;195:255\u201364.","journal-title":"Psychopharmacology"},{"key":"1589_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/0091-3057(91)90367-B","volume":"40","author":"E Castaneda","year":"1991","unstructured":"Castaneda E, Moss DE, Oddie SD, Whishaw IQ. THC does not affect striatal dopamine release: microdialysis in freely moving rats. Pharm Biochem Behav. 1991;40:587\u201391.","journal-title":"Pharm Biochem Behav"},{"key":"1589_CR42","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/j.1471-4159.2008.05503.x","volume":"106","author":"C Cadoni","year":"2008","unstructured":"Cadoni C, Valentini V, Di Chiara G. Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission. J Neurochemistry. 2008;106:1586\u201393.","journal-title":"J Neurochemistry"},{"key":"1589_CR43","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1146\/annurev.pharmtox.47.120505.105140","volume":"47","author":"AE Fleckenstein","year":"2007","unstructured":"Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharm Toxicol. 2007;47:681\u201398.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"1589_CR44","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1523\/JNEUROSCI.4901-04.2006","volume":"26","author":"BJ Venton","year":"2006","unstructured":"Venton BJ, Seipel AT, Phillips PE, Wetsel WC, Gitler D, Greengard P, et al. Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci: Off J Soc Neurosci. 2006;26:3206\u20139.","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"1589_CR45","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/j.celrep.2018.04.062","volume":"23","author":"Y Yan","year":"2018","unstructured":"Yan Y, Peng C, Arvin MC, Jin XT, Kim VJ, Ramsey MD, et al. Nicotinic cholinergic receptors in VTA glutamate neurons modulate excitatory transmission. Cell Rep. 2018;23:2236\u201344.","journal-title":"Cell Rep"},{"key":"1589_CR46","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1097\/00001756-199809140-00033","volume":"9","author":"E Charpantier","year":"1998","unstructured":"Charpantier E, Barneoud P, Moser P, Besnard F, Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. Neuroreport. 1998;9:3097\u2013101.","journal-title":"Neuroreport."},{"key":"1589_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145702003188","volume":"6","author":"B Schilstrom","year":"2003","unstructured":"Schilstrom B, Rawal N, Mameli-Engvall M, Nomikos GG, Svensson TH. Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes. Int J Neuropsychopharmacol. 2003;6:1\u201311.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1589_CR48","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1152\/jn.00760.2007","volume":"98","author":"JR Keath","year":"2007","unstructured":"Keath JR, Iacoviello MP, Barrett LE, Mansvelder HD, McGehee DS. Differential modulation by nicotine of substantia nigra versus ventral tegmental area dopamine neurons. J Neurophysiol. 2007;98:3388\u201396.","journal-title":"J Neurophysiol"},{"key":"1589_CR49","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/acer.13483","volume":"41","author":"B Soderpalm","year":"2017","unstructured":"Soderpalm B, Lido HH, Ericson M. The glycine receptor-A functionally important primary brain target of ethanol. Alcohol Clin Exp Res. 2017;41:1816\u201330.","journal-title":"Alcohol Clin Exp Res"},{"key":"1589_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-642-28720-6_170","volume":"13","author":"B Soderpalm","year":"2013","unstructured":"Soderpalm B, Ericson M. Neurocircuitry involved in the development of alcohol addiction: the dopamine system and its access points. Curr Top Behav Neurosci. 2013;13:127\u201361.","journal-title":"Curr Top Behav Neurosci"},{"key":"1589_CR51","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1523\/JNEUROSCI.12-02-00483.1992","volume":"12","author":"SW Johnson","year":"1992","unstructured":"Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci: Off J Soc Neurosci. 1992;12:483\u20138.","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"1589_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2004.09.005","volume":"48","author":"YJ Cao","year":"2005","unstructured":"Cao YJ, Surowy CS, Puttfarcken PS. Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release. Neuropharmacology. 2005;48:72\u201379.","journal-title":"Neuropharmacology."},{"key":"1589_CR53","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1476-5381.1992.tb09067.x","volume":"105","author":"ME Benwell","year":"1992","unstructured":"Benwell ME, Balfour DJ. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharm. 1992;105:849\u201356.","journal-title":"Br J Pharm"},{"key":"1589_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/0972-6748.119646","volume":"21","author":"PS Bhat","year":"2012","unstructured":"Bhat PS, Ryali V, Srivastava K, Kumar SR, Prakash J, Singal A. Alcoholic hallucinosis. Ind Psychiatry J. 2012;21:155\u20137.","journal-title":"Ind Psychiatry J"},{"key":"1589_CR55","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1176\/ajp.144.10.1340","volume":"144","author":"C Schmauss","year":"1987","unstructured":"Schmauss C, Yassouridis A, Emrich HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144:1340\u20132.","journal-title":"Am J Psychiatry"},{"key":"1589_CR56","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0140-6736(77)90319-1","volume":"2","author":"MS Gold","year":"1977","unstructured":"Gold MS, Donabedian RK, Dillard M Jr, Slobetz FW, Riordan CE, Kleber HD. Antipsychotic effect of opiate agonists. Lancet. 1977;2:398\u20139.","journal-title":"Lancet."},{"key":"1589_CR57","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"JM Beaulieu","year":"2011","unstructured":"Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharm Rev. 2011;63:182\u2013217.","journal-title":"Pharm Rev"},{"key":"1589_CR58","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1530-0277.2009.00942.x","volume":"33","author":"DL Robinson","year":"2009","unstructured":"Robinson DL, Howard EC, McConnell S, Gonzales RA, Wightman RM. Disparity between tonic and phasic ethanol-induced dopamine increases in the nucleus accumbens of rats. Alcohol Clin Exp Res. 2009;33:1187\u201396.","journal-title":"Alcohol Clin Exp Res"},{"key":"1589_CR59","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/syn.10226","volume":"49","author":"I Boileau","year":"2003","unstructured":"Boileau I, Assaad JM, Pihl RO, Benkelfat C, Leyton M, Diksic M, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse. 2003;49:226\u201331.","journal-title":"Synapse."},{"key":"1589_CR60","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00213-014-3720-1","volume":"232","author":"BG Oberlin","year":"2015","unstructured":"Oberlin BG, Dzemidzic M, Tran SM, Soeurt CM, O'Connor SJ, Yoder KK, et al. Beer self-administration provokes lateralized nucleus accumbens dopamine release in male heavy drinkers. Psychopharmacology. 2015;232:861\u201370.","journal-title":"Psychopharmacology"},{"key":"1589_CR61","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/jcbfm.2014.209","volume":"35","author":"S Aalto","year":"2015","unstructured":"Aalto S, Ingman K, Alakurtti K, Kaasinen V, Virkkala J, N\u00e5gren K, et al. Intravenous ethanol increases dopamine release in the ventral striatum in humans: PET study using bolus-plus-infusion administration of [(11)C]raclopride. J Cereb Blood Flow Metab. 2015;35:424\u201331.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1589_CR62","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.drugalcdep.2016.01.001","volume":"160","author":"KK Yoder","year":"2016","unstructured":"Yoder KK, Albrecht DS, Dzemidzic M, Normandin MD, Federici LM, Graves T, et al. Differences in IV alcohol-induced dopamine release in the ventral striatum of social drinkers and nontreatment-seeking alcoholics. Drug Alcohol Depend. 2016;160:163\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"1589_CR63","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/mp.2010.56","volume":"16","author":"VA Ramchandani","year":"2011","unstructured":"Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry. 2011;16:809\u201317.","journal-title":"Mol Psychiatry"},{"key":"1589_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/npp.2008.87","volume":"34","author":"AL Brody","year":"2009","unstructured":"Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL, et al. Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology. 2009;34:282\u20139.","journal-title":"Neuropsychopharmacology."},{"key":"1589_CR65","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1176\/appi.ajp.161.7.1211","volume":"161","author":"AL Brody","year":"2004","unstructured":"Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry. 2004;161:1211\u20138.","journal-title":"Am J Psychiatry"},{"key":"1589_CR66","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1017\/S1461145707008103","volume":"11","author":"H Takahashi","year":"2008","unstructured":"Takahashi H, Fujimura Y, Hayashi M, Takano H, Kato M, Okubo Y, et al. Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol. 2008;11:413\u20137.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1589_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ntr\/nts029","volume":"15","author":"EF Domino","year":"2013","unstructured":"Domino EF, Ni L, Domino JS, Yang W, Evans C, Guthrie S, et al. Denicotinized versus average nicotine tobacco cigarette smoking differentially releases striatal dopamine. Nicotine Tob Res. 2013;15:11\u201321.","journal-title":"Nicotine Tob Res"},{"key":"1589_CR68","doi-asserted-by":"publisher","first-page":"16851","DOI":"10.1523\/JNEUROSCI.3661-14.2014","volume":"34","author":"KP Cosgrove","year":"2014","unstructured":"Cosgrove KP, Wang S, Kim SJ, McGovern E, Nabulsi N, Gao H, et al. Sex differences in the brain\u2019s dopamine signature of cigarette smoking. J Neurosci: Off J Soc Neurosci. 2014;34:16851\u20135.","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"1589_CR69","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/syn.20419","volume":"61","author":"AJ Montgomery","year":"2007","unstructured":"Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM. The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse. 2007;61:637\u201345.","journal-title":"Synapse."},{"key":"1589_CR70","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.biopsych.2019.03.965","volume":"86","author":"PA Spagnolo","year":"2019","unstructured":"Spagnolo PA, Kimes A, Schwandt ML, Shokri-Kojori E, Thada S, Phillips KA, et al. Striatal dopamine release in response to morphine: a [(11)C]Raclopride positron emission tomography study in healthy men. Biol Psychiatry. 2019;86:356\u201364.","journal-title":"Biol Psychiatry"},{"key":"1589_CR71","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1192\/bjp.bp.107.041228","volume":"193","author":"MR Daglish","year":"2008","unstructured":"Daglish MR, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M, et al. Brain dopamine response in human opioid addiction. Br J Psychiatry. 2008;193:65\u201372.","journal-title":"Br J Psychiatry"},{"key":"1589_CR72","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/adb.12073","volume":"19","author":"BJ Watson","year":"2014","unstructured":"Watson BJ, Taylor LG, Reid AG, Wilson SJ, Stokes PR, Brooks DJ, et al. Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. Addict Biol. 2014;19:1032\u201340.","journal-title":"Addict Biol"},{"key":"1589_CR73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.neuroimage.2009.06.029","volume":"48","author":"PR Stokes","year":"2009","unstructured":"Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage. 2009;48:186\u201390.","journal-title":"Neuroimage."},{"key":"1589_CR74","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.neuroimage.2010.04.274","volume":"52","author":"PR Stokes","year":"2010","unstructured":"Stokes PR, Egerton A, Watson B, Reid A, Breen G, Lingford-Hughes A, et al. Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage. 2010;52:1521\u20137.","journal-title":"Neuroimage."},{"key":"1589_CR75","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00213-015-3915-0","volume":"232","author":"MG Bossong","year":"2015","unstructured":"Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR. Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology. 2015;232:2723\u20139.","journal-title":"Psychopharmacology"},{"key":"1589_CR76","doi-asserted-by":"publisher","first-page":"e70378","DOI":"10.1371\/journal.pone.0070378","volume":"8","author":"R Kuepper","year":"2013","unstructured":"Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven JM, et al. Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study. PLoS ONE. 2013;8:e70378.","journal-title":"PLoS ONE"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01589-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01589-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01589-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T10:08:05Z","timestamp":1675678085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01589-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01589-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"12 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}